Version · CLP
Version in force
Made by Regulation (EU) 2018/1480 32018R1480 on EUR-Lex (external, EUR-Lex)
Version 15 of 31 recorded for CLP.
First seen by emendrix on , when it first read this version; that is not a legal date.
1 change in this version
Consolidated versions 02008R1272-20200101 → 02008R1272-20200501. v1 is the previous version, v2 this one.
What changed
Annex VI Harmonised classification and labelling for certain hazardous substances, Modified§
Explanation, written by a model and checked against the cited text
The explanatory note above the Table 3 column headers was changed from a statement about a converted acute toxicity point estimate referencing Annex I Table 3.1.2 to a statement explaining that ATEs for oral and dermal exposure routes are expressed in mg/kg bodyweight.
The table column heading was also altered, splitting the earlier single heading covering specific concentration limits, M-factors and Acute Toxicity Estimates into a heading for specific concentration limits, M-factors and ATEs together with a separate Notes heading.
The remainder of the visible text, including the substance entries themselves, is unchanged between the two versions, and both texts are truncated before any further differences could be observed.
Cited: Annex VI, v1 (external, EUR-Lex) · Annex VI, v2 (external, EUR-Lex)
v1 is the previous version, v2 this one.
Each CAS and EC number in these tables links to its own page, which lists every entry that prints it across the acts this record holds.
16 entries added, 18 amended, 0 removed.
1 row carries no key and is not compared.
16 entries added
| Identifiers | Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | |||||||
| Index No 604-094-00-XCAS 5912-86-7CAS 5932-68-3CAS 97-54-1EC 202-590-7EC 227-633-7EC 227-678-2 | 604-094-00-X | isoeugenol; [1] (E)-2-methoxy-4-(prop-1-enyl)phenol; [2] (Z)-2-methoxy-4-(prop-1-enyl)phenol [3] | 202-590-7 [1] 227-678-2 [2] 227-633-7 [3] | 97-54-1 [1] 5932-68-3 [2] 5912-86-7 [3] | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1A; H317: C ≥ 0,01 % | ||
| Index No 607-724-00-1CAS 240494-71-7 | 607-724-00-1 | 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin | — | 240494-71-7 | Acute Tox. 4 Acute Tox. 3 STOT SE 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H332 H301 H370 (nervous system) H373 H400 H410 | GHS06 GHS08 GHS09 Dgr | H332 H301 H370 (nervous system) H373 H410 | M = 100 M = 100 | ||
| Index No 607-725-00-7CAS 65733-16-6 | 607-725-00-7 | isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene | — | 65733-16-6 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 1 | ||
| Index No 607-726-00-2CAS 243973-20-8 | 607-726-00-2 | pinoxaden (ISO); 8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate | — | 243973-20-8 | Repr. 2 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 STOT SE 3 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 3 | H361d H332 H302 H319 H335 H317 H400 H412 | GHS08 GHS07 GHS09 Wng | H361d H332 H302 H319 H335 H317 H410 | inhalation: ATE = 4,63 mg/L (dusts or mists) oral: ATE = 500 mg/kg bw M = 1 | ||
| Index No 607-727-00-8CAS 7696-12-0EC 231-711-6 | 607-727-00-8 | tetramethrin (ISO); (1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate | 231-711-6 | 7696-12-0 | Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H371 (nervous system) (inhalation) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H371 (nervous system) (inhalation) H410 | M = 100 M = 100 | ||
| Index No 607-728-00-3CAS 1166-46-7EC 214-619-0 | 607-728-00-3 | (1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate | 214-619-0 | 1166-46-7 | Carc. 2 Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H371 (nervous system) (inhalation) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H371 (nervous system) (inhalation) H410 | M = 100 M = 100 | ||
| Index No 607-729-00-9CAS 208465-21-8 | 607-729-00-9 | mesosulfuron-methyl (ISO); methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate; | — | 208465-21-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 100 M = 100 | ||
| Index No 607-730-00-4CAS 148477-71-8 | 607-730-00-4 | spirodiclofen (ISO); 3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate | — | 148477-71-8 | Carc. 1B Repr. 2 STOT RE 2 Skin Sens. 1B Aquatic Chronic 1 | H350 H361f H373 H317 H410 | GHS08 GHS07 GHS09 Dgr | H350 H361f H373 H317 H410 | M = 10 | ||
| Index No 607-731-00-XCAS 2302-17-2EC 218-953-8 | 607-731-00-X | sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium | 218-953-8 | 2302-17-2 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 1 M = 1 | ||
| Index No 607-732-00-5CAS 69-72-7EC 200-712-3 | 607-732-00-5 | salicylic acid | 200-712-3 | 69-72-7 | Repr. 2 Acute Tox. 4 Eye Dam. 1 | H361d H302 H318 | GHS08 GHS07 GHS05 Dgr | H361d H302 H318 | |||
| Index No 608-068-00-9CAS 958647-10-4 | 608-068-00-9 | flutianil (ISO); (2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile | — | 958647-10-4 | Aquatic Chronic 1 | H410 | GHS09 Wng | H410 | M = 100 | ||
| Index No 612-293-00-8EC 447-920-2 | 612-293-00-8 | reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine | 447-920-2 | - | Repr. 2 Acute Tox. 4 Skin Corr. 1B Eye Dam. 1 | H361f H302 H314 H318 | GHS08 GHS07 GHS05 Dgr | H361f H302 H314 | EUH071 | ||
| Index No 613-326-00-9CAS 2682-20-4EC 220-239-6 | 613-326-00-9 | 2-methylisothiazol-3(2H)-one | 220-239-6 | 2682-20-4 | Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H311 H301 H314 H318 H317 H400 H410 | GHS05 GHS06 GHS09 Dgr | H330 H311 H301 H314 H317 H410 | EUH071 | Skin Sens. 1A; H317: C ≥ 0,0015 % M = 10 M = 1 | |
| Index No 613-327-00-4CAS 422556-08-9 | 613-327-00-4 | pyroxsulam (ISO); N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide | — | 422556-08-9 | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 100 M = 100 | ||
| Index No 613-328-00-XCAS 1072-63-5EC 214-012-0 | 613-328-00-X | 1-vinylimidazole | 214-012-0 | 1072-63-5 | Repr. 1B | H360D | GHS08 Dgr | H360D | Repr. 1B; H360D: C ≥ 0,03 % | ||
| Index No 616-224-00-2CAS 348635-87-0 | 616-224-00-2 | amisulbrom (ISO); 3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide | — | 348635-87-0 | Carc. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H319 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H319 H410 | M = 10 M = 10 | ||
18 entries amended
| Identifiers | Version | Index No | Chemical name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATEs | Notes | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | ||||||||
| Index No 006-044-00-7CAS 34123-59-6EC 251-835-4 | Before | 006-044-00-7 | isoproturon (ISO); 3-(4-isopropylphenyl)-1,1-dimethylurea | 251-835-4 | 34123-59-6 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 10 | ||
| After | 006-044-00-7 | isoproturon (ISO); 3-(4-isopropylphenyl)-1,1-dimethylurea | 251-835-4 | 34123-59-6 | Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H373 (blood) H400 H410 | GHS08 GHS09 Wng | H351 H373 (blood) H410 | M = 10M = 10 | |||
| Index No 015-101-00-5CAS 732-11-6EC 211-987-4 | Before | 015-101-00-5 | phosmet (ISO);
| 211-987-4 | 732-11-6 | Acute Tox. 4 | M = 100 | |||||
| After | 015-101-00-5 | phosmet (ISO); S-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate; O,O-dimethyl-S-phthalimidomethyl phosphorodithioate | 211-987-4 | 732-11-6 | Repr. 2 Acute Tox. 4 Acute Tox. 3 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f H332 H301 H370 (nervous system) H400 H410 | GHS08 GHS06 GHS09 Dgr | H361f H332 H301 H370 (nervous system) H410 | M = 100M = 100 | |||
| Index No 016-096-00-2CAS 79277-27-3 | Before | 016-096-00-2 | thifensulfuron-methyl (ISO); methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate | — | 79277-27-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | |||
| After | 016-096-00-2 | thifensulfuron-methyl (ISO); methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate | — | 79277-27-3 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 100 M = 100 | |||
| Index No 017-011-00-1CAS 7681-52-9EC 231-668-3 | Before | 017-011-00-1 | sodium hypochlorite, | 231-668-3 | 7681-52-9 | Skin Corr. 1B Aquatic Acute 1 | H314 H400 | GHS05 GHS09 Dgr | H314
| EUH031 | EUH031: C | B |
| After | 017-011-00-1 | sodium hypochlorite, solution … % Cl active | 231-668-3 | 7681-52-9 | Skin Corr. 1B Eye Dam. 1 Aquatic Acute 1Aquatic Chronic 1 | H314 H318 H400H410 | GHS05 GHS09 Dgr | H314 H410 | EUH031 | M = 10 M = 1 EUH031: C ≥ 5 % | B | |
| Index No 025-002-00-9CAS 7722-64-7EC 231-760-3 | Before | 025-002-00-9 | potassium permanganate | 231-760-3 | 7722-64-7 | Ox. Sol. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H272 H302 H400 H410 | GHS03 GHS07 GHS09 Dgr | H272 H302 H410 | |||
| After | 025-002-00-9 | potassium permanganate | 231-760-3 | 7722-64-7 | Ox. Sol. 2 Repr. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 | H272 H361d H302 H400 H410 | GHS03 GHS08 GHS07 GHS09 Dgr | H272 H361d H302 H410 | ||||
| Index No 603-180-00-4CAS 67-97-0EC 200-673-2 | Before | 603-180-00-4 | colecalciferol; | 200-673-2 | 67-97-0 | Acute Tox. 2 | H330
| GHS06 GHS08 Dgr | H330
| |||
| After | 603-180-00-4 | colecalciferol; cholecalciferol; vitamin D3 | 200-673-2 | 67-97-0 | Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 STOT RE 1 | H330 H310 H300 H372 | GHS06 GHS08 Dgr | H330 H310 H300 H372 | inhalation: ATE = 0,05 mg/L (dusts or mists) dermal: ATE = 50 mg/kg bw oral: ATE = 35 mg/kg bw STOT RE 1; H372: C ≥ 3 % STOT RE 2; H373: 0,3 % ≤ C < 3 % | |||
| Index No 604-014-00-3CAS 59-50-7EC 200-431-6 | Before | 604-014-00-3 | chlorocresol; 4-chloro-m-cresol; 4-chloro-3-methylphenol | 200-431-6 | 59-50-7 | Acute Tox. 4 | GHS05
| |||||
| After | 604-014-00-3 | chlorocresol; 4-chloro-m-cresol; 4-chloro-3-methylphenol | 200-431-6 | 59-50-7 | Acute Tox. 4 Skin Corr. 1C Eye Dam. 1 STOT SE 3 Skin Sens. 1B Aquatic Acute 1Aquatic Chronic 3 | H302 H314 H318 H335 H317 H400H412 | GHS07 GHS05 GHS09 Dgr | H302 H314 H335 H317 H410 | M = 1 | |||
| Index No 604-016-00-4CAS 120-80-9EC 204-427-5 | Before | 604-016-00-4 | 1,2-dihydroxybenzene; pyrocatechol | 204-427-5 | 120-80-9 | Acute Tox. | ||||||
| After | 604-016-00-4 | 1,2-dihydroxybenzene; pyrocatechol | 204-427-5 | 120-80-9 | Carc. 1Β Muta. 2 Acute Tox. 3 Acute Tox. 3 Skin Irrit. 2 Eye Irrit. 2 | H350 H341 H311 H301 H315 H319 | GHS08 GHS06 Dgr | H350 H341 H311 H301 H315 H319 | oral: ATE = 300 mg/kg bw dermal: ATE = 600 mg/kg bw | |||
| Index No 604-090-00-8CAS 98-54-4EC 202-679-0 | Before | 604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 | Repr. 2 Skin Irrit. 2 Eye Dam. 1 | H361f H315 H318 | GHS08 GHS05 Dgr | H361f H315 H318 | |||
| After | 604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 | Repr. 2 Skin Irrit. 2 Eye Dam. 1Aquatic Chronic 1 | H361f H315 H318H410 | GHS08 GHS05 GHS09 Dgr | H361f H315 H318H410 | M = 1 | |||
| Index No 605-003-00-6CAS 75-07-0EC 200-836-8 | Before | 605-003-00-6 | acetaldehyde; ethanal | 200-836-8 | 75-07-0 | Flam. Liq. 1
Carc. | H224
| GHS02 GHS08 GHS07 Dgr | H224
| |||
| After | 605-003-00-6 | acetaldehyde; ethanal | 200-836-8 | 75-07-0 | Flam. Liq. 1 Carc. 1B Muta. 2 STOT SE 3Eye Irrit. 2 | H224 H350 H341 H335 H319 | GHS02 GHS08 GHS07 Dgr | H224 H350 H341 H335 H319 | ||||
| Index No 606-047-00-9CAS 119313-12-1EC 404-360-3 | Before | 606-047-00-9 | 404-360-3 | 119313-12-1 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09
| H410 | ||||
| After | 606-047-00-9 | 2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone | 404-360-3 | 119313-12-1 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360D H400 H410 | GHS08 GHS09 Dgr | H360D H410 | ||||
| Index No 607-096-00-9CAS 108-31-6EC 203-571-6 | Before | 607-096-00-9 | maleic anhydride | 203-571-6 | 108-31-6 | Acute Tox. 4 | H302 H314 H334 H317 | GHS08
GHS05
| H302 H314 H334 H317 | |||
| After | 607-096-00-9 | maleic anhydride | 203-571-6 | 108-31-6 | Acute Tox. 4 STOT RE 1 Skin Corr. 1B Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1A | H302 H372 (respiratory system) (inhalation) H314 H318 H334 H317 | GHS07 GHS08 GHS05 Dgr | H302 H372 (respiratory system) (inhalation) H314 H334 H317 | EUH071 | Skin Sens. 1A; H317: C ≥ 0,001 % | ||
| Index No 607-103-00-5CAS 108-30-5EC 203-570-0 | Before | 607-103-00-5 | succinic anhydride | 203-570-0 | 108-30-5 | Acute Tox. 4 | H302
| GHS07
| H302
| |||
| After | 607-103-00-5 | succinic anhydride | 203-570-0 | 108-30-5 | Acute Tox. 4 Skin Corr. 1 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 | H302 H314 H318 H334 H317 | GHS07 GHS05 GHS08 Dgr | H302 H314 H334 H317 | EUH071 | |||
| Index No 607-113-00-XCAS 97-86-9EC 202-613-0 | Before | 607-113-00-X | isobutyl methacrylate | 202-613-0 | 97-86-9 | Flam. Liq. 3
| H226
| GHS02
GHS07
| H226
| D | ||
| After | 607-113-00-X | isobutyl methacrylate | 202-613-0 | 97-86-9 | Flam. Liq. 3 STOT SE 3 Skin Irrit. 2 Skin Sens. 1B | H226 H335 H315 H317 | GHS02 GHS07 Wng | H226 H335 H315 H317 | D | |||
| Index No 607-373-00-4CAS 119738-06-6CAS 200509-41-7EC 414-200-4 | Before | 607-373-00-4 | 414-200-4 | GHS08
GHS07
GHS09
| ||||||||
| After | 607-373-00-4 | quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate | 414-200-4 | 200509-41-7 | Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361fd H302 H373 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361fd H302 H373 H410 | M = 1 M = 1 | |||
| Index No 613-167-00-5CAS 55965-84-9 | Before | 613-167-00-5 | reaction mass | — | 55965-84-9 | Acute Tox. 3 | GHS06 GHS05 GHS09 Dgr | Skin Corr. | ||||
| After | 613-167-00-5 | reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1) | — | 55965-84-9 | Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H310 H301 H314 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H310 H301 H314 H317 H410 | EUH071 | Skin Corr. 1C; H314: C ≥ 0,6 % Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 % Eye Dam. 1; H318: C ≥ 0,6 % Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 % Skin Sens. 1A; H317: C ≥ 0,0015 %M = 100 M = 100 | B | |
| Index No 613-205-00-0CAS 60207-90-1EC 262-104-4 | Before | 613-205-00-0 | 262-104-4 | 60207-90-1 | Acute Tox. 4 | H302 H317 H400 H410 | GHS07
GHS09
| H302 H317 H410 | ||||
| After | 613-205-00-0 | propiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole | 262-104-4 | 60207-90-1 | Repr. 1B Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H360D H302 H317 H400 H410 | GHS08 GHS07 GHS09 Dgr | H360D H302 H317 H410 | M = 1 M = 1 | |||
| Index No 614-001-00-4CAS 54-11-5EC 200-193-3 | Before | 614-001-00-4 | nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine | 200-193-3 | 54-11-5 | Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 | H330 H310 H300 H411 | GHS06 GHS09 Dgr | H330 H310 H300 H411 | inhalation:
ATE = | ||
| After | 614-001-00-4 | nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine | 200-193-3 | 54-11-5 | Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 Aquatic Chronic 2 | H330 H310 H300 H411 | GHS06 GHS09 Dgr | H330 H310 H300 H411 | inhalation: ATE = 0,19 mg/L (dusts or mists) dermal: ATE = 70 mg/kg bw oral: ATE = 5 mg/kgbw | |||
Text from EUR-Lex, before and after
Previous version, in force 1 January 2020 02008R1272-20200101 → this version, in force 1 May 2020 02008R1272-20200501
compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere
ANNEX VI
Harmonised classification and labelling for certain hazardous substances
Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3.
… 273 unchanged lines …
Table 3.2: The list of harmonised classification and labelling of hazardous substances from Annex I to Directive 67/548/EEC.
Table 3
List of harmonised classification and labelling of hazardous substances
Converted acute toxicity point estimate according to Table 3.1.2 of Annex I.
Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors Notes ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.
Index No Chemical name EC No CAS No Classification Labelling Specific Conc. Limits, M-factors and ATEs
Notes
Hazard Class and
Category Code(s) Hazard statement Code(s) Pictogram, Signal Word Code(s) Hazard statement Code(s) Suppl. Hazard statement Code(s)
001-001-00-9 hydrogen 215-605-7 1333-74-0 Flam. Gas 1
… 897 unchanged lines …
H315
H410 006-044-00-7 isoproturon (ISO);
3-(4-isopropylphenyl)-1,1-dimethylurea 251-835-4 34123-59-6 Carc. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1 H351
H373 (blood)
H400
H410 GHS08
GHS09
Wng H351
H410 M = 10 006-045-00-2 methomyl (ISO); H373 (blood)
H410 M = 10
M = 10 006-045-00-2 methomyl (ISO);
1-(methylthio)ethylideneamino N-methylcarbamate 240-815-0 16752-77-5 Acute Tox. 2 *
Aquatic Acute 1
Aquatic Chronic 1 H300
… 2,483 unchanged lines …
Wng H361f*** H302
H317
H410 M=1000 015-101-00-5 phosmet (ISO);
O, O-dimethyl phthalimidomethyl S-phosphorodithioate 211-987-4 732-11-6 Acute Tox. 4 *
Acute Tox. 4 * S-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate;
O,O-dimethyl-S-phthalimidomethyl phosphorodithioate 211-987-4 732-11-6 Repr. 2
Acute Tox. 4
Acute Tox. 3
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1 H312
H302 Aquatic Chronic 1 H361f
H332
H301
H370 (nervous system)
H400
H410 GHS07 H410 GHS08
GHS06
GHS09
Wng H312
H302
H410 M = 100 015-102-00-0 tris(2-chloroethyl)phosphate 204-118-5 115-96-8 Carc. 2 Dgr H361f
H332
H301
H370 (nervous system)
H410 M = 100
M = 100 015-102-00-0 tris(2-chloroethyl)phosphate 204-118-5 115-96-8 Carc. 2
Repr. 1B
Acute Tox. 4 *
Aquatic Chronic 2 H351
… 1,449 unchanged lines …
methyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate — 79277-27-3 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 016-097-00-8 1-amino-2-methyl-2-propanethiol hydrochloride 434-480-1 32047-53-3 Acute Tox. 4 * Wng H410 M = 100
M = 100 016-097-00-8 1-amino-2-methyl-2-propanethiol hydrochloride 434-480-1 32047-53-3 Acute Tox. 4 *
Skin Corr. 1B
Skin Sens. 1
Aquatic Chronic 3 H302
… 109 unchanged lines …
H302 GHS03
GHS07
Dgr H271
H302 017-011-00-1 sodium hypochlorite, solution… % Cl active 231-668-3 7681-52-9 Skin Corr. 1B
Aquatic Acute 1 H314
H400 GHS05 H302 017-011-00-1 sodium hypochlorite, solution … % Cl active 231-668-3 7681-52-9 Skin Corr. 1B
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1 H314
H318
H400
H410 GHS05
GHS09
Dgr H314
H400 EUH031 EUH031: C ≥5 % B H410 EUH031 M = 10
M = 1
EUH031:
C ≥ 5 % B
017-012-00-7 calcium hypochlorite 231-908-7 7778-54-3 Ox. Sol. 2
Acute Tox. 4 *
Skin Corr. 1B
… 601 unchanged lines …
H302 GHS07
Wng H332
H302 025-002-00-9 potassium permanganate 231-760-3 7722-64-7 Ox. Sol. 2
Acute Tox. 4 *
Aquatic Acute 1
Aquatic Chronic 1 H272 Repr. 2
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 H272
H361d
H302
H400
H410 GHS03
GHS08
GHS07
GHS09
Dgr H272
H361d
H302
H410 025-003-00-4 manganese sulphate 232-089-9 7785-87-7 STOT RE 2 *
Aquatic Chronic 2 H373 **
… 7,125 unchanged lines …
Dgr H330
H311
H301
H372 ** 603-180-00-4 colecalciferol; Vitamin D3 200-673-2 67-97-0 Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 H330
H311
H301
H372 ** GHS06 H372 ** 603-180-00-4 colecalciferol;
cholecalciferol;
vitamin D3 200-673-2 67-97-0 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2
STOT RE 1 H330
H310
H300
H372 GHS06
GHS08
Dgr H330
H311
H301
H372 ** 603-181-00-X tert-butyl methyl ether; MTBE; 2-methoxy-2-methylpropane 216-653-1 1634-04-4 Flam. Liq. 2 H310
H300
H372 inhalation:
ATE = 0,05 mg/L (dusts or mists)
dermal:
ATE = 50 mg/kg bw
oral:
ATE = 35 mg/kg bw
STOT RE 1; H372: C ≥ 3 %
STOT RE 2; H373: 0,3 % ≤ C < 3 % 603-181-00-X tert-butyl methyl ether; MTBE; 2-methoxy-2-methylpropane 216-653-1 1634-04-4 Flam. Liq. 2
Skin Irrit. 2 H225
H315 GHS02
GHS07
… 487 unchanged lines …
H315
H410 *
Eye Irrit. 2; H319:C≥5 % Skin Irrit. 2;
H315: C≥5 % 604-014-00-3 chlorocresol; 4-chloro-m-cresol; 4-chloro-3-methylphenol 200-431-6 59-50-7 Acute Tox. 4 * Acute Tox. 4 * H315: C≥5 % 604-014-00-3 chlorocresol;
4-chloro-m-cresol;
4-chloro-3-methylphenol 200-431-6 59-50-7 Acute Tox. 4
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1 H312
H302 STOT SE 3
Skin Sens. 1B Aquatic Acute 1
Aquatic Chronic 3 H302
H314
H318
H335
H317
H400 GHS05
GHS07 H400
H412 GHS07
GHS05
GHS09
Dgr H312
H302
H318 Dgr H302
H314
H335
H317
H400 * 604-015-00-9 2,2'-methylenebis-(3,4,6-trichlorophenol); hexachlorophene 200-733-8 70-30-4 Acute Tox. 3 * H410 M = 1 604-015-00-9 2,2'-methylenebis-(3,4,6-trichlorophenol); hexachlorophene 200-733-8 70-30-4 Acute Tox. 3 *
Acute Tox. 3 * Aquatic Acute 1
Aquatic Chronic 1 H311
H301
H400
H410 GHS06
GHS09
Dgr H311
H301
H410 * 604-016-00-4 1,2-dihydroxybenzene; pyrocatechol 204-427-5 120-80-9 Acute Tox. 4 * Acute Tox. 4 *
Eye Irrit. 2
Skin Irrit. 2 H312
H302
H319
H315 GHS07
Wng H312
H302
H319
H315 604-017-00-X 2,4,5-trichlorophenol 202-467-8 95-95-4 Acute Tox. 4 * H410 * 604-016-00-4 1,2-dihydroxybenzene;
pyrocatechol 204-427-5 120-80-9 Carc. 1Β
Muta. 2
Acute Tox. 3
Acute Tox. 3
Skin Irrit. 2
Eye Irrit. 2 H350
H341
H311
H301
H315
H319 GHS08
GHS06
Dgr H350
H341
H311
H301
H315
H319 oral:
ATE = 300 mg/kg bw
dermal:
ATE = 600 mg/kg bw 604-017-00-X 2,4,5-trichlorophenol 202-467-8 95-95-4 Acute Tox. 4 *
Eye Irrit. 2
Skin Irrit. 2
Aquatic Acute 1
… 456 unchanged lines …
H336
H410 604-090-00-8 4-tert-butylphenol 202-679-0 98-54-4 Repr. 2
Skin Irrit. 2
Eye Dam. 1 H361f Eye Dam. 1
Aquatic Chronic 1 H361f
H315
H318 GHS08 H318
H410 GHS08
GHS05
GHS09
Dgr H361f
H315
H318 604-091-00-3 etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether 407-980-2 80844-07-1 Lact. H318
H410 M = 1 604-091-00-3 etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether 407-980-2 80844-07-1 Lact.
Aquatic Acute 1
Aquatic Chronic 1 H362
H400
… 55 unchanged lines …
H318
H373 (kidney)
H410 M = 1
M = 100 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 M = 100 604-094-00-X isoeugenol; [1]
(E)-2-methoxy-4-(prop-1-enyl)phenol; [2]
(Z)-2-methoxy-4-(prop-1-enyl)phenol [3] 202-590-7 [1]
227-678-2 [2]
227-633-7 [3] 97-54-1 [1]
5932-68-3 [2]
5912-86-7 [3] Skin Sens. 1A H317 GHS07
Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2
Acute Tox. 3* Acute Tox. 3* Acute Tox. 3*
Skin Corr. 1B
Skin Sens. 1 H350
… 25 unchanged lines …
GHS07
Dgr H228
H361d *** H335 T
605-003-00-6 acetaldehyde; ethanal 200-836-8 75-07-0 Flam. Liq. 1
Carc. 2
Eye Irrit. 2
STOT SE 3 H224
H351
H319
H335 GHS02 605-003-00-6 acetaldehyde;
ethanal 200-836-8 75-07-0 Flam. Liq. 1
Carc. 1B
Muta. 2
STOT SE 3
Eye Irrit. 2 H224
H350
H341
H335
H319 GHS02
GHS08
GHS07
Dgr H224
H351
H319
H335 605-004-00-1 2,4,6-trimethyl-1,3,5-trioxane; paraldehyde 204-639-8 123-63-7 Flam. Liq. 3 H226 GHS02 H350
H341
H335
H319 605-004-00-1 2,4,6-trimethyl-1,3,5-trioxane; paraldehyde 204-639-8 123-63-7 Flam. Liq. 3 H226 GHS02
Wng H226 605-005-00-7 2,4,6,8-tetramethyl-1,3,5,7-tetraoxacyclooctane; metaldehyde 203-600-2 108-62-3 Flam. Sol. 2
Acute Tox. 4 * H228
H302 GHS02
… 632 unchanged lines …
Wng H410 606-046-00-3 reaction mass of cis-and trans-cyclohexadec-8-en-1-one 401-700-2 3100-36-5 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 606-047-00-9 2-benzyl-2-dimethylamino-4-morpholinobutyrophenone 404-360-3 119313-12-1 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 606-048-00-4 2'-anilino-3'-methyl-6'-dipentylaminospiro(isobenzofuran-1(1H),9'-xanthen)-3-one 406-480-1 — Aquatic Chronic 4 H413 — H413 606-049-00-X 4-(trans-4-propylcyclohexyl)acetophenone 406-700-6 78531-61-0 Skin Sens. 1 Wng H410 606-047-00-9 2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone 404-360-3 119313-12-1 Repr. 1B
Aquatic Acute 1
Aquatic Chronic 1 H360D
H400
H410 GHS08
GHS09
Dgr H360D
H410 606-048-00-4 2'-anilino-3'-methyl-6'-dipentylaminospiro(isobenzofuran-1(1H),9'-xanthen)-3-one 406-480-1 — Aquatic Chronic 4 H413 — H413 606-049-00-X 4-(trans-4-propylcyclohexyl)acetophenone 406-700-6 78531-61-0 Skin Sens. 1
Aquatic Chronic 4 H317
H413 GHS07
Wng H317
… 1,367 unchanged lines …
H319
H335
H315
H317 Skin Sens. 1; H317: C ≥0,1 % 607-096-00-9 maleic anhydride 203-571-6 108-31-6 Acute Tox. 4 * H317 Skin Sens. 1; H317: C ≥0,1 % 607-096-00-9 maleic anhydride 203-571-6 108-31-6 Acute Tox. 4
STOT RE 1
Skin Corr. 1B
Eye Dam. 1
Resp. Sens. 1
Skin Sens. 1 H302 Skin Sens. 1A H302
H372 (respiratory system) (inhalation)
H314
H318
H334
H317 GHS07
GHS08
GHS05
Dgr H302
H372 (respiratory system) (inhalation)
H314
H334
H317 GHS08
GHS05
GHS07
Dgr H302
H314
H334
H317 607-097-00-4 benzene-1,2,4-tricarboxylic acid 1,2-anhydride; trimellitic anhydride 209-008-0 552-30-7 STOT SE 3 H317 EUH071 Skin Sens. 1A; H317: C ≥ 0,001 % 607-097-00-4 benzene-1,2,4-tricarboxylic acid 1,2-anhydride; trimellitic anhydride 209-008-0 552-30-7 STOT SE 3
Eye Dam. 1
Resp. Sens. 1
Skin Sens. 1 H335
… 55 unchanged lines …
Dgr H318
H334
H317 C
607-103-00-5 succinic anhydride 203-570-0 108-30-5 Acute Tox. 4 *
Eye Irrit. 2
STOT SE 3 H302
H319
H335 GHS07
Wng H302
H319
H335 *
Eye Irrit. 2; H319: C ≥ 1 % STOT SE 3; H335: C ≥ 1 % 607-104-00-0 cyclopentane-1,2,3,4-tetracarboxylic dianhydride 227-964-7 6053-68-5 Eye Irrit. 2 607-103-00-5 succinic anhydride 203-570-0 108-30-5 Acute Tox. 4
Skin Corr. 1
Eye Dam. 1
Resp. Sens. 1
Skin Sens. 1 H302
H314
H318
H334
H317 GHS07
GHS05
GHS08
Dgr H302
H314
H334
H317 EUH071 607-104-00-0 cyclopentane-1,2,3,4-tetracarboxylic dianhydride 227-964-7 6053-68-5 Eye Irrit. 2
STOT SE 3 H319
H335 GHS07
Wng H319
… 87 unchanged lines …
H315
H317 * D
607-113-00-X isobutyl methacrylate 202-613-0 97-86-9 Flam. Liq. 3
Eye Irrit. 2
STOT SE 3
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1 H226
H319 Skin Sens. 1B H226
H335
H315
H317
H400 GHS02 H317 GHS02
GHS07
GHS09
Wng H226
H319
H335
H315
H317
H400 D H317 D
607-114-00-5 ethylene dimethacrylate 202-617-2 97-90-5 STOT SE 3
Skin Sens. 1 H335
H317 GHS07
… 1,584 unchanged lines …
H317 607-370-00-8 2-[[2-(acetyloxy)-3-(1,1-dimethyl-ethyl)-5-methylphenyl]methyl]-6-(1,1-dimethylethyl)-4-methylphenol 412-210-3 41620-33-1 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 607-371-00-3 3-ethyl 5-methyl 4-(2-chlorophenyl)-1,4-dihydro-2-[2-(1,3-dihydro-1,3-dioxo-(2)isoindol-2-yl)-ethoxymethyl]-6-methyl-3,5-pyridinedicarboxylate 413-410-3 88150-62-3 Aquatic Chronic 4 H413 — H413 607-372-00-9 ethoxylated bisphenol A di-(norbornene carboxylate) 412-410-0 — Aquatic Chronic 3 H412 — H412 607-373-00-4 (±) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate 414-200-4 119738-06-6 Muta. 2
Repr. 1B
Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1
Aquatic Chronic 1 H341
H360Df Wng H410 607-371-00-3 3-ethyl 5-methyl 4-(2-chlorophenyl)-1,4-dihydro-2-[2-(1,3-dihydro-1,3-dioxo-(2)isoindol-2-yl)-ethoxymethyl]-6-methyl-3,5-pyridinedicarboxylate 413-410-3 88150-62-3 Aquatic Chronic 4 H413 — H413 607-372-00-9 ethoxylated bisphenol A di-(norbornene carboxylate) 412-410-0 — Aquatic Chronic 3 H412 — H412 607-373-00-4 quizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate 414-200-4 200509-41-7 Carc. 2
Repr. 2
Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1 H351
H361fd
H302
H373 ** H400 H373
H400
H410 GHS08
GHS07
GHS09
Dgr H341
H360Df Wng H351
H361fd
H302
H373 ** H410 607-374-00-X 5-amino-2,4,6-triiodo-1,3-benzenedicarbonyldichloride 417-220-1 37441-29-5 Skin Sens. 1 H373
H410 M = 1
M = 1 607-374-00-X 5-amino-2,4,6-triiodo-1,3-benzenedicarbonyldichloride 417-220-1 37441-29-5 Skin Sens. 1
Aquatic Chronic 2 H317
H411 GHS07
GHS09
… 1,721 unchanged lines …
H310
H300
H410 M = 10000
M = 10000 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 M = 10000 607-724-00-1 2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin — 240494-71-7 Acute Tox. 4
Acute Tox. 3
STOT SE 1
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1 H332
H301
H370 (nervous system)
H373
H400
H410 GHS06
GHS08
GHS09
Dgr H332
H301
H370 (nervous system)
H373
H410 M = 100
M = 100 607-725-00-7 isopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene — 65733-16-6 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 M = 1
M = 1 607-726-00-2 pinoxaden (ISO);
8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate — 243973-20-8 Repr. 2
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
STOT SE 3
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 3 H361d
H332
H302
H319
H335
H317
H400
H412 GHS08
GHS07
GHS09
Wng H361d
H332
H302
H319
H335
H317
H410 inhalation:
ATE = 4,63 mg/L (dusts or mists)
oral:
ATE = 500 mg/kg bw
M = 1 607-727-00-8 tetramethrin (ISO);
(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate 231-711-6 7696-12-0 Carc. 2
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1 H351
H302
H371 (nervous system) (inhalation)
H400
H410 GHS08
GHS07
GHS09
Wng H351
H302
H371 (nervous system) (inhalation)
H410 M = 100
M = 100 607-728-00-3 (1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate 214-619-0 1166-46-7 Carc. 2
Acute Tox. 4
STOT SE 2
Aquatic Acute 1
Aquatic Chronic 1 H351
H302
H371 (nervous system) (inhalation)
H400
H410 GHS08
GHS07
GHS09
Wng H351
H302
H371 (nervous system) (inhalation)
H410 M = 100
M = 100 607-729-00-9 mesosulfuron-methyl (ISO);
methyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate; — 208465-21-8 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
Wng H410 M = 100
M = 100 607-730-00-4 spirodiclofen (ISO);
3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate — 148477-71-8 Carc. 1B
Repr. 2
STOT RE 2
Skin Sens. 1B
Aquatic Chronic 1 H350
H361f
H373
H317
H410 GHS08
GHS07
GHS09
Dgr H350
H361f
H373
H317
H410 M = 10 607-731-00-X sodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium 218-953-8 2302-17-2 Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H317
H400
H410 GHS07
GHS09
Wng H317
H410 M = 1
M = 1 607-732-00-5 salicylic acid 200-712-3 69-72-7 Repr. 2
Acute Tox. 4
Eye Dam. 1 H361d
H302
H318 GHS08
GHS07
GHS05
Dgr H361d
H302
H318 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2
Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 *
Eye Irrit. 2 H225
H332
… 508 unchanged lines …
H319
H410 M = 10 A
608-067-00-3 3,7-dimethylocta-2,6-dienenitrile 225-918-0 5146-66-7 Muta. 1B H340 GHS08
Dgr H340 609-001-00-6 1-nitropropane 203-544-9 108-03-2 Flam. Liq. 3 Dgr H340 608-068-00-9 flutianil (ISO);
(2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile — 958647-10-4 Aquatic Chronic 1 H410 GHS09
Wng H410 M = 100 609-001-00-6 1-nitropropane 203-544-9 108-03-2 Flam. Liq. 3
Acute Tox. 4 *
Acute Tox. 4 *
Acute Tox. 4 * H226
… 5,532 unchanged lines …
H411 EUH071 8
9
612-292-00-2 methylhydrazine 200-471-4 60-34-4 Carc. 1B H350 GHS08
Dgr H350 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 Dgr H350 612-293-00-8 reaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine 447-920-2 - Repr. 2
Acute Tox. 4
Skin Corr. 1B
Eye Dam. 1 H361f
H302
H314
H318 GHS08
GHS07
GHS05
Dgr H361f
H302
H314 EUH071 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2
Carc. 1B
Muta. 1B
Acute Tox. 2 *
… 1,400 unchanged lines …
GHS09
Dgr H360D
H410 M = 1000
M = 1000 613-167-00-5 reaction mass of: 5-chloro-2- methyl-4-isothiazolin-3-one [EC no. 247-500-7]and 2-methyl-2H -isothiazol-3- one [EC no. 220-239-6] (3:1); reaction mass of: 5-chloro-2- methyl-4-isothiazolin-3-one [EC no. 247-500-7]and 2-methyl-4-isothiazolin-3- one [EC no. 220-239-6] (3:1) — 55965-84-9 Acute Tox. 3 *
Acute Tox. 3 *
Acute Tox. 3 *
Skin Corr. 1B
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H331
H311 M = 1000 613-167-00-5 reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1) — 55965-84-9 Acute Tox. 2
Acute Tox. 2
Acute Tox. 3
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1A Aquatic Acute 1
Aquatic Chronic 1 H330
H310
H301
H314
H318
H317
H400
H410 GHS06
GHS05
GHS09
Dgr H331
H311 Dgr H330
H310
H301
H314
H317
H410 Skin Corr. 1B; H314: C ≥0,6 %
Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %
Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %
Skin Sens. 1; H317: C ≥ 0,0015 % 613-168-00-0 1-vinyl-2-pyrrolidone 201-800-4 88-12-0 Carc. 2 H410 EUH071 Skin Corr. 1C; H314: C ≥ 0,6 %
Skin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %
Eye Dam. 1; H318: C ≥ 0,6 %
Eye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100 B
613-168-00-0 1-vinyl-2-pyrrolidone 201-800-4 88-12-0 Carc. 2
Acute Tox. 4 *
Acute Tox. 4 *
Acute Tox. 4 * STOT RE 2 *
… 316 unchanged lines …
H410 GHS08
GHS09
Wng H361d*** H373**
H410 M = 1000 613-205-00-0 propiconazole(ISO);
(±) 1-[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-ylmethyl]-1H—1,2,4-triazole 262-104-4 60207-90-1 Acute Tox. 4 * H410 M = 1000 613-205-00-0 propiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole 262-104-4 60207-90-1 Repr. 1B
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H302 Aquatic Chronic 1 H360D
H302
H317
H400
H410 GHS07 H410 GHS08
GHS07
GHS09
Wng H302 Dgr H360D
H302
H317
H410 613-206-00-6 fenamidone (ISO); H410 M = 1
M = 1 613-206-00-6 fenamidone (ISO);
(S)-5-methyl-2-methylthio-5-phenyl-3-phenylamino-3,5-dihydroimidazol-4-one — 161326-34-7 Aquatic Acute 1
Aquatic Chronic 1 H400
H410 GHS09
… 807 unchanged lines …
H301
H336
H410 M = 100
M = 100 614-001-00-4 nicotine (ISO); M = 100 613-326-00-9 2-methylisothiazol-3(2H)-one 220-239-6 2682-20-4 Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
Skin Corr. 1B
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1 H330
H311
H301
H314
H318
H317
H400
H410 GHS05
GHS06
GHS09
Dgr H330
H311
H301
H314
H317
H410 EUH071 Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 10
M = 1 613-327-00-4 pyroxsulam (ISO);
N-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide — 422556-08-9 Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1 H317
H400
H410 GHS07
GHS09
Wng H317
H410 M = 100
M = 100 613-328-00-X 1-vinylimidazole 214-012-0 1072-63-5 Repr. 1B H360D GHS08
Dgr H360D Repr. 1B; H360D: C ≥ 0,03 % 614-001-00-4 nicotine (ISO);
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2
Acute Tox. 2
Acute Tox. 2
Aquatic Chronic 2 H330
H310
H300
H411 GHS06
GHS09
Dgr H330
H310
H300
H411 inhalation:
ATE = 0.19 mg/L (dusts or mists) ATE = 0,19 mg/L (dusts or mists)
dermal:
ATE = 70 mg/kg ATE = 70 mg/kg bw
oral:
ATE
= 5 mg/kg 614-002-00-X salts of nicotine — — Acute Tox. 2 * ATE = 5 mg/kg bw 614-002-00-X salts of nicotine — — Acute Tox. 2 *
Acute Tox. 1
Acute Tox. 2 *
Aquatic Chronic 2 H330
… 1,827 unchanged lines …
Dgr H351
H360D
H302
H411 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H411 616-224-00-2 amisulbrom (ISO);
3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide — 348635-87-0 Carc. 2
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1 H351
H319
H400
H410 GHS08
GHS07
GHS09
Wng H351
H319
H410 M = 10
M = 10 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242
H225
H341 GHS02
GHS08
… 24,954 unchanged lines …
S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N
R: 50/53
S: 60-61
The full entry is committed at eu/32008R1272/CHANGELOG.md.